Current Report Filing (8-k)
September 23 2022 - 4:07PM
Edgar (US Regulatory)
0000744452
false
0000744452
2022-09-22
2022-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 22, 2022
Applied DNA Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation) |
001-36745
(Commission File Number) |
59-2262718
(IRS Employer
Identification No.) |
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of principal executive offices; zip code)
Registrant’s telephone number, including
area code:
631-240-8800
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value |
|
APDN |
|
The Nasdaq Stock Market |
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 22, 2022, Applied DNA Sciences, Inc.
(the “Company”) held its 2022 annual meeting of stockholders (the “2022 Annual Meeting”). The following proposals
were voted on and were approved by the Company’s stockholders, except with respect to proposal 2 which was not approved, at the
2022 Annual Meeting with the stockholders having voted as set forth below:
I. To elect seven directors to serve until the
2023 annual meeting of stockholders or until their respective successors are duly elected and qualified.
|
|
FOR |
|
WITHHELD |
|
BROKER NON-VOTES |
James A. Hayward |
|
1,613,361 |
|
375,993 |
|
2,773,010 |
Robert B. Catell |
|
1,615,523 |
|
373,831 |
|
2,773,010 |
Joseph D. Ceccoli |
|
1,621,939 |
|
367,415 |
|
2,773,010 |
Scott L. Anchin |
|
1,614,389 |
|
374,965 |
|
2,773,010 |
Yacov A. Shamash |
|
1,527,522 |
|
461,832 |
|
2,773,010 |
Sanford R. Simon |
|
1,609,331 |
|
380,023 |
|
2,773,010 |
Elizabeth M. Schmalz |
|
1,600,880 |
|
388,474 |
|
2,773,010 |
II. To grant the board of directors of the Company
the discretionary authority to amend the Company’s certificate of incorporation, as amended, to effect a reverse stock split of
the Company’s common stock and to reduce the number of authorized shares of the Company’s common stock to 50,000,000.
FOR |
|
AGAINST |
|
ABSTAIN |
3,639,252 |
|
1,093,517 |
|
29,595 |
III. To approve, on a non-binding advisory basis,
the compensation of the Company’s named executive officers.
FOR |
|
AGAINST |
|
ABSTAIN |
|
BROKER NON-VOTES |
1,386,134 |
|
524,487 |
|
78,733 |
|
2,773,010 |
IV. To ratify the appointment of Marcum LLP as
the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2022.
FOR |
|
AGAINST |
|
ABSTAIN |
4,516,454 |
|
82,725 |
|
163,185 |
Each of the foregoing voting results from the 2022
Annual Meeting is final.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: September 23, 2022 |
APPLIED DNA SCIENCES, INC. |
|
|
|
|
By: |
/s/ James A. Hayward |
|
Name: |
James A. Hayward |
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024